866-997-4948(US-Canada Toll Free)

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 62 Pages

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)-Pipeline Review, H2 2017

Summary

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Orexin Receptor Type 2-Pipeline Review, H2 2017, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)-Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene. OX2 is a G-protein coupled receptor expressed exclusively in the brain. OX2 binds both orexin A and orexin B neuropeptides. OX2 is involved in the central feedback mechanism that regulates feeding behavior. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 4 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Insomnia, Narcolepsy, Sleep Disorders and Major Depressive Disorder.

Furthermore, this report also reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
- The report reviews Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)-Overview
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)-Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)-Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)-Companies Involved in Therapeutics Development
Actelion Pharmaceuticals Ltd
Eisai Co Ltd
Evotec AG
Heptares Therapeutics Ltd
Idorsia Ltd
Johnson & Johnson
Merck & Co Inc
OptiNose US Inc
Yangtze River Pharmaceutical Group
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)-Drug Profiles
ACT-541468-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DORA-12-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-6641-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lemborexant-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8133-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-021-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seltorexant-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin Receptor 2 for Narcolepsy-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Orexin 1 and 2 Receptors for Insomnia-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suvorexant-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YNT-185-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)-Dormant Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)-Discontinued Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)-Product Development Milestones
Featured News & Press Releases
Sep 05, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
Jul 28, 2017: ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia
Oct 28, 2016: Eisai To Initiate Phase II Clinical Study Of Dual Orexin Receptor Antagonist Lemborexant In Patients With Irregular Sleep-Wake Rhythm Disorder And Dementia
Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia
Jun 01, 2016: Minerva Neurosciences to Present data on MIN-202
Mar 11, 2016: Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202
Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients
Feb 01, 2016: OptiNose Announces Pipeline Project to Evaluate Nose-to-Brain Application of Bi-Directional Breath Powered Technology Selected for Norwegian Government Funding
Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder
Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial With Central Nervous System Product Candidate MIN-202
Sep 24, 2015: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist
Jun 16, 2015: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist
Feb 03, 2015: Mercks Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States
Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia
Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Actelion Pharmaceuticals Ltd, H2 2017
Pipeline by Eisai Co Ltd, H2 2017
Pipeline by Evotec AG, H2 2017
Pipeline by Heptares Therapeutics Ltd, H2 2017
Pipeline by Idorsia Ltd, H2 2017
Pipeline by Johnson & Johnson, H2 2017
Pipeline by Merck & Co Inc, H2 2017
Pipeline by OptiNose US Inc, H2 2017
Pipeline by Yangtze River Pharmaceutical Group, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *